ISSN: 1368-7646

Journal Home

Journal Guideline

Drug Resistance Updates Q1 Unclaimed

Churchill Livingstone United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Drug Resistance Updates is a bimonthly publication that contains thought-provoking reviews on important developments in drug resistance in infectious disease and cancer as well as novel drugs and strategies to overcome drug resistance. It covers both basic research and clinical aspects of drug resistance, and involves disciplines as diverse as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology and clinical medicine. It has an SJR impact factor of 4,391.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: Bi Monthly

Categories: Cancer Research (Q1) Infectious Diseases (Q1) Oncology (Q1) Pharmacology (Q1) Pharmacology (medical) (Q1) Pharmacology (medical) (Q1)

Price

3072 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

4,391

SJR Impact factor

125

H Index

28

Total Docs (Last Year)

65

Total Docs (3 years)

5855

Total Refs

1576

Total Cites (3 years)

65

Citable Docs (3 years)

23.73

Cites/Doc (2 years)

209.11

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

The Lancet Infectious Diseases Q1
Clinical Microbiology Reviews Q1
Clinical Infectious Diseases Q1
The Lancet HIV Q1
Journal of Infection Q1

Compare this journals

Aims and Scope

Best articles by citations

Drug resistance in Cryptococcus neoformans

Drug resistance in Giardia: clinical versus laboratory isolates

Drug resistance in Leishmania: similarities and differences to other organisms

Drug resistance in Pneumocystis carinii: an emerging problem

Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.

Drugs and drug resistance in African trypanosomiasis

Chemically modified tetracyclines as inhibitors of matrix metalloproteinases

Definitive proof for a role of pfmdr 1 in quinoline resistance in Plasmodium falciparum

39thInterscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) San Francisco, USA, 26-29 September 1999

The 90th Annual Meeting of the American Association for Cancer Research (AACR) Philadelphia, USA, 10-14 April 1999

Bacterial energetics and antimicrobial resistance

Reversing drug resistance in bcl-2-expressing tumor cells by depleting glutathione

SHOW MORE ARTICLES

Clinical cancer research 2000: new agents and therapies

Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?

Clinical cancer research 2001: new agents and therapies

Subcellular targeting regulates the function of caspase-activated protein kinases in apoptosis

Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?

Clinical cancer research 2002: new agents and therapies

Antifungal drug susceptibility testing and resistance in Aspergillus

ATP-binding cassette transporters: from multidrug resistance to genetic disease, Gosau, Austria, 20-27 February 1999

Erratum

Phenotypic antibiotic tolerance of Staphylococcus aureus in implant-related infections: relationship with in vitro colonization of artificial surfaces

New developments: Chloroquine-resistance in Plasmodium falciparum

cDNA Technologies and their application to drug resistance research: power, potential and problems